CLOs on the Move

LEXEO Therapeutics

www.lexeotx.com

 
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.lexeotx.com
  • 430 East 29th Street 14th Floor
    New York, AB USA 10016
  • Phone: 212.547.9879

Executives

Name Title Contact Details

Similar Companies

Luknova

Luknova is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akonni Biosystems

Akonni Biosystems is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cidara

Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company`s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara`s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases

Affymax

Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The Company's product candidate, Hematide, is designed to treat anemia associated with chronic renal